TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02642796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric nerve stimulation
Description: The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound.
Study: NCT02763072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlighten Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excel V Laser
Study: NCT03282968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REWIRE
Description: First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercises
Description: The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
Study: NCT00506818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifactorial vascular-risk-factor-intervention
Study: NCT00836017

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered as part of the study.
Study: NCT02235220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composite resin restoration
Description: Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted.
Study: NCT01701037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: 150 mg given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: 2 mg given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02442271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study: NCT01349101

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
Study: NCT02777515

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: using electronic cigarette
Description: Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram
Study: NCT04420338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: rapid serological tests carried out

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: rapid serological tests carried out

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum tube collection
Description: SARS-COV2 seroconversion assay
Study: NCT00522340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
Study: NCT01575717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Description: Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Description: Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
Study: NCT04606836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: See group descriptions
Study: NCT02126930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharma consult
Description: Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
Study: NCT02108210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04153058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted AEG Radical Gastrectomy
Description: Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Assisted AEG Radical Gastrectomy
Description: Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
Study: NCT02613546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse
Study: NCT00961038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
Study: NCT02613546

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control therapy
Description: The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
Study: NCT01612169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) Group
Description: The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Plus Contingency Management (PN+CM) Group
Description: Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
Study: NCT00457743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate (SU011248)
Description: SU011248
Study: NCT02933944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG02-treatment
Study: NCT00609219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous EBV specific CTLs
Description: 30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2
Study: NCT04237740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relenvatinib
Description: The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
Study: NCT01486784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
Study: NCT02297542

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flu Vaccine
Study: NCT04426838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference
Description: The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference
Description: The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
Study: NCT04093258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lenses
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix® Multifocal Contact Lenses Plus HydraGlyde®
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix® Multifocal Contact Lenses Plus HydraGlyde®
Description: CONTROL
Study: NCT01017809

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
Study: NCT02126930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Patients randomized to this arm will receive care in the habitual manner.
Study: NCT03907800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
Study: NCT05130073

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo PET/CT
Study: NCT02899117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: There are 4 yoga sessions completed with a certified instructor during cancer treatment
Study: NCT05130073

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: PROCEDURE
Intervention: Follow-Up
Description: Undergo follow-up

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00660218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Description: Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy (IMRT or 3D-CRT)
Description: radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
Study: NCT03156218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of FiO2
Description: Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of FiO2
Description: Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
Study: NCT04350684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umifenovir
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
Study: NCT00661349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
Study: NCT04350684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-β 1a
Description: This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β 1a
Description: This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standards of Care
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standards of Care
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study: NCT04052061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 t-haNK
Description: CD19 t-haNK Suspension for Infusion
Study: NCT04505488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASD Screening Parent ENgagement Intervention Program (ASPEN)
Description: The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
Study: NCT01471171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: 1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
Study: NCT00845858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: 30 minutes before meals and at bedtime for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: 30 minutes before meals and at bedtime for 4 weeks
Study: NCT02160821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal Epidural
Description: Ultrasound Guided Caudal Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: Ultrasound Guided Transversus Abdominis Plane Block
Study: NCT00845858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 minutes before meals and at bedtime
Study: NCT05253729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ESWT
Description: F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
Study: NCT04946383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Quercetin
Description: Dasatinib plus Quercetin
Study: NCT04580069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic drainage
Description: The interventions follow the validated techniques normally used in international rehabilitation
Study: NCT00661349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
Study: NCT03298152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CERASMART Endocrown
Description: Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emax Endocrown
Description: Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
Study: NCT02658201

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Ultrafast MRI to assess constipation
Study: NCT02275767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 50% cortical/50% cancellous FDBA
Description: Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 100% cortical FDBA
Description: Ridge preservation after tooth extraction using 100% cortical FDBA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 100% cancellous FDBA
Description: Ridge preservation after tooth extraction using 100% cancellous FDBA
Study: NCT04580069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic drainage
Description: The interventions follow the validated techniques normally used in international rehabilitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphatic drainage
Description: The interventions follow the validated techniques normally used in international rehabilitation
Study: NCT01843400

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Patients treated with Regorafenib under practical manner for colorectal cancer.